Oxford University Press

SHERPA: Yellow

People

  1. Drilon
    Drilon
  2. Motzer
    Motzer
  3. Mellinghoff
    Mellinghoff
  4. Shuman
    Shuman
  5. Rosenblum
    Rosenblum
  6. Dunkel
    Dunkel
  7. Karajannis
    Karajannis
  8. Saltz
    Saltz
  9. Souweidane
    Souweidane
  10. Panageas
    Panageas

Groups

  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)
  7. Department of Pathology and Laboratory Medicine (415)
  8. Gastrointestinal Oncology Service (386)
  9. Genitourinary Oncology Service (367)
  10. Tow Center for Developmental Oncology (TCDO) (352)
Search Within
Formats
  1. Journal Article (2131)
  2. Meeting Abstract (2072)
  3. Book Section (192)
  4. Review (92)
  5. Editorial (84)
  6. Guidelines (36)
  7. Correspondence (26)
  8. Book Whole (18)
  9. Conference Paper (15)
  10. Research Letter (10)
Groups
  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)

More Groups

People
  1. Lisa De Angelis (119)
  2. Alexander Drilon (108)
  3. Robert Motzer (96)
  4. Ingo Mellinghoff (93)
  5. Stewart Shuman (88)
  6. Marc Rosenblum (87)

More People

Years
  1. 2025 (129)
  2. 2024 (304)
  3. 2023 (320)
  4. 2022 (331)
  5. 2021 (323)
  6. 2020 (325)

More Years

Publications
  1. Annals of Oncology (1670)
  2. Neuro-Oncology (855)
  3. JNCI: Journal of the National Cancer Institute (492)
  4. Nucleic Acids Research (210)
  5. Clinical Infectious Diseases (140)
  6. American Journal of Clinical Pathology (106)

More Publications

Results (4676)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Efficacy and safety of tabelecleucel in patients with EpsteinBarr Virus-associated leiomyosarcomas (EBV(+)LMS)
    Meeting Abstract

    Kurlander, L. S.; Srinivasan, A.; Ghobadi, A.; Suser, S.; Doubrovina, E.; Boulad, F.; Mascarenhas, L.; Laquaglia, M.; Price, A.; Behr, G.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Use of nuclear-localized androgen receptor splice variant 7 protein in CTCs after 1st androgen receptor signaling inhibitor (ARSi) as a predictive biomarker for overall survival on a second ARSi or taxane chemotherapy in metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Scher, H. I.; Graf, R. P.; Hulling, M.; Carbone, E.; Dittamore, R.
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Autoimmunity and benefit from trastuzumab treatment in breast cancer: Results from the HERA phase III trial
    Meeting Abstract

    Sonnenblick, A.; Bailey, A.; Uziely, B.; Untch, M.; Smith, I.; Gianni, L.; Baselga, J.; Jackisch, C.; Cameron, D.; Bell, R.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Post-treatment biopsies show evidence of cell cycle arrest and immune cell infiltration into tumors of ladiratuzumab vedotin-treated advanced breast cancer patients
    Meeting Abstract

    Specht, J.; Pusztai, L.; Forero-Torres, A.; Mita, M.; Weise, A.; Krop, I.; Grosse-Wilde, A.; Wang, Z.; Li, M.; Hengel, S.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Safety and tolerability of atezolizumab (atezo) plus bevacizumab (bev) vs sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC): Pooled analysis of IMmotion150 and IMmotion151
    Meeting Abstract

    Suarez, C.; Choueiri, T. K.; McDermott, D. F.; Escudier, B.; Atkins, M. B.; Powles, T. B.; Rini, B. I.; Motzer, R. J.; Pal, S. K.; Fong, L.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • ATTAIN: Phase III study of etirinotecan pegol (EP) vs treatment of physician's choice (TPC) in patients (pts) with metastatic breast cancer (MBC) who have stable brain metastases (BM) previously treated with an anthracycline, a taxane, and capecitabine (ATC)
    Meeting Abstract

    Tripathy, D.; Tolaney, S. M.; Seidman, A. D.; Anders, C. K.; Ibrahim, N. K.; Rugo, H. S.; Twelves, C. J.; Dieras, V.; Mùˆller, V.; Hannah, A. L.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Characterization of response to nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (pts) with previously untreated advanced renal cell carcinoma (aRCC): CheckMate 214
    Meeting Abstract

    Rini, B. I.; Tannir, N. M.; Escudier, B.; McDermott, D. F.; Grimm, M. O.; Porta, C.; Powles, T.; Kollmannsberger, C. K.; Gurney, H. P.; Tykodi, S. S.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • EV-201: A single-arm, open-label, multicenter study of enfortumab vedotin for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor therapy
    Meeting Abstract

    Rosenberg, J. E.; Balar, A.; O'Donnell, P. H.; Heath, E. I.; Hahn, N. M.; Cavazos, N. M.; Melhem-Bertrandt, A.; Petrylak, D. P.
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Nivolumab (N) alone or in combination with ipilimumab (I) in patients (pts) with platinum-pretreated metastatic urothelial carcinoma (mUC), including the nivolumab 1 mg/kg + ipilimumab 3 mg/kg expansion from CheckMate 032
    Meeting Abstract

    Rosenberg, J. E.; Sharma, P.; de Braud, F. G. M.; Basso, U.; Calvo, E.; Bono, P.; Morse, M.; Ascierto, P. A.; Lopez-Martin, J. A.; Brossart, P.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • BAYOU: Phase II study of efficacy and safety of durvalumab plus olaparib as first-line therapy in cisplatin-ineligible patients (pts) with stage iv urothelial cancer (UC)
    Meeting Abstract

    Rosenberg, J. E.; Bajorin, D. F.; Smith, A.; D'Cruz, C.; Lanasa, M.
    Annals of Oncology (2018)

    Fulltext@MSK | Save